BBIO FY 2023 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-88.0% YoY

Gross Profit

$7M73.7% margin

Operating Income

-$607M-6528.8% margin

Net Income

-$643M-6913.9% margin

EPS (Diluted)

$-3.95

Cash Flow

Operating Cash Flow

-$528M

Free Cash Flow

-$529M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$546M

Total Liabilities

$1.9B

Stockholders' Equity

-$1.4B

Cash & Equivalents

$376M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$78M	-88.0%
Gross Profit	$7M	$74M	-90.8%
Operating Income	-$607M	-$512M	-18.6%
Net Income	-$643M	-$481M	-33.7%